Meeting
2016 ASCO Annual Meeting
Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.
Authors
John Paul Flores
Tufts Medical Center, Boston, MA
John Paul Flores , Paul Mathew
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02500901
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5095)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5095
Abstract #
TPS5095
Poster Bd #
441a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).
First Author: Johann S. De Bono
Poster
2020 Genitourinary Cancers Symposium
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
First Author: Marit Vermunt
Poster
2019 ASCO Annual Meeting
Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).
First Author: Mamta Parikh